The ‘Networking & Innovation Day’ has consolidated itself as the reference benchmark to promote open innovation of the UB group Blog Post

Nearly 200 participants from 100 public and private entities gathered at the Parc Cientific de Barcelona (PCB) as part of the 2nd edition of the ‘Networking & Innovation Day‘. The seminar was organized by the University of Barcelona (UB), the Bosch i Gimpera Foundation (FBG), the Science and Technology Centers of the UB (CCTiUB) and the PCB with the aim to create a reference benchmark in the transfer of knowledge and technology that promotes public-private partnership, partnership agreements and open innovation among actors in the research and innovation system of UB Group and the business world, in general.

Iproteos closes the first ‘crowdfunding’ campaign of the Spanish biotech sector Blog Post

The biotech Iproteos -located at the Parc Cientific de Barcelona- has managed to successfully close an innovative funding campaign based on equity crowdfunding with the aim of raising € 100,000 for the development of a new drug to stop progression and reverse the cognitive deficits associated with schizophrenia: IPR019. The funds raised will allow the biotech -a spin-off from the University of Barcelona (UB) and the Institute for Research in Biomedicine (IRB Barcelona) – complete the preclinical non-regulatory stage of the compound to begin clinical trials in 2016.

 

La Fundació GAEM organitza la 5a edició de les jornades ‘Volem Saber’TO TRANSLATE >>> Blog Post

El proper dijous 2 d’octubre a les 17.00h se celebra la cinquena edició de les jornades de divulgació científiques. En aquesta ocasió el Parc Científic de Barcelona, serà el lloc que acollirà la reunió entre científics, investigadors, administració pública i pacients, per parlar dels avenços que s’estan duent a terme en el camp de la investigació biomèdica en Esclerosi Múltiple.

Discovery of why colon cancer metastasis always follows the same invasive pattern Blog Post

A team of scientists led by Roger Gomis, ICREA researcher and head of the Growth Control and Cancer Metastasis Group at the Institute for Research in Biomedicine (IRB Barcelona), has identified the genes that favour staggered colon cancer metastasis. Published on Sunday in the journal Nature Cell Biology (doi:10.1038/ncb2977), in addition to Gomis, the authors include Angel R. Nebreda, ICREA and BBVA Cancer Research Professor, and Eduard Batlle, ICREA Professor and head of the Colorectal Cancer Lab, both at IRB Barcelona.

SOM Biotech develops a drug for Amyloidosis in collaboration with the Vall d’Hebron Research Institute Blog Post

The and the biopharmaceutical , based at the Parc Científic de Barcelona (PCB), have signed an agreement to jointly develop the clinical phase of a drug for transthyretin Amyloidosis (ATTR). The collaboration starts with the execution of a proof of concept in 20 healthy voluntiers and patients affected by the polineuropatic form of the disease – which will confirm the efficacy and safety of compound SOM0226. The product, a repositioned drug developed by SOM Biotech, may be effective for all variants of the ATTR and has been designated recently orphan drug by the Food and Drug Administration (FDA) of United States.

 

IPC selected the study led by Santamaria as one of the top five papers published in 2013 Blog Post

Streptococcal antigens (Streptococcus pyogenes) might be directly involved in the pathological mechanisms that result in the appearance of psoriasis lesions. Psoriasis is a chronic cutaneous inflammatory disease. Its prevalence is high and it affects considerably patients’ quality of life. This is the main conclusion of the scientific paper published by the translational research group on immunodermatology led by Luis Francisco Santamaria Babí, tenure-track lecturer of Immunology of the Department of Physiology and Immunology at the Faculty of Biology and the Barcelona Science Park. The paper has been selected by the International Psoriasis Council (IPC) as one of the top five papers published on 2013 about the disease. The article was published on the Journal of Investigative Dermatology (doi: 10.1038/jid.2012.418), the highest impact factor journal in dermatology.

SOM Biotech licenses a product for glioblastoma to Argon Pharma pharmaceuticals Blog Post

The pharmaceutical start-up –based at the Barcelona Science Park (PCB) and specialised in the discovery and development of new indications for existing drugs– has licensed to the biotech , also located at the PCB, a new product with potential properties for the treatment of multiple glioblastoma, the most common malignant brain tumor.SOM0777 is an inhibitor of αvβ3 and αvβ5 integrins, proteins actively involved in the binding of cells to their environment, so that their blockade may be beneficial in the treatment of various cancers.

Lilly organitza al PCB la jornada ‘Atenció Integral del pacient amb osteoporosis a Catalunya. Un repte o una realitat’TO TRANSLATE >>> Blog Post

Encara que existeixen certs protocols d’abordatge integral de pacients majors amb fractura d’os que han demostrat ser eficaços, les unitats d’Ortogeriatría són encara un repte a Catalunya. Aquesta és una de les conclusions de la jornada ‘Atenció Integral del pacient amb osteoporosis a Catalunya. Un repte o una realitat’, organitzada per la farmacèutica Lilly, i que va tenir lloc ahir en el Parc Científic de Barcelona amb més de XXXX assistents.